Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Compound 32"'
Autor:
Xiaoguang Chen, Jing Jin, Ming Ji, Bailing Xu, Jie Zhou, Xiaoyu Wang, Ran Cao, Hailong Zhao, Li Sheng, Yan Li, Chen Xianhong
Publikováno v:
Journal of Medicinal Chemistry. 64:16711-16730
Inhibiting PARP-1/2 offered an important arsenal for cancer treatments via interfering with DNA repair of cancer cells. Novel PARP-1/2 inhibitors were designed by capitalizing on methyl- or ethyl-substituted piperizine ring to capture the characteris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7bfe6fd872b9839efe4c778cd4e61e6
https://doi.org/10.1021/acs.jmedchem.1c01522
https://doi.org/10.1021/acs.jmedchem.1c01522
Autor:
Edward J. Hennessy, Marianne Schimpl, Emma Rivers, Paul D. Smith, Elizabeth Hardaker, Ann T. Doherty, Nichola L. Davies, Jon Travers, Qianxiu Zhu, Beth Williamson, Graham Smith, Lorraine Mooney, Helen Musgrove, Kristin Goldberg, Muireann Coen, Anne-Laure Lainé, Xiefeng Jiang, Philip Hopcroft, Yuting Zheng, Robert I Troup, George Hodgson, Nicola Lindsay, Lindsay McMurray, Olga Collingwood, Stephen D. Wilkinson, Sharon Tentarelli, Guang He, Philip B. Rawlins, Roshini Markandu, Jon Winter-Holt, Josephine Walton, Ankur Karmokar, J. Willem M. Nissink, Yumeng Mao, Dejian Yang, Alexander Pflug, Gary Fairley, Scott Boyd, Cheng Wang, Anne Jackson, Martin R. Brown, William McCoull, Neville McLean, Venkatesh Pilla Reddy
Publikováno v:
Journal of Medicinal Chemistry. 64:13524-13539
Inhibition of Mer and Axl kinases has been implicated as a potential way to improve the efficacy of current immuno-oncology therapeutics by restoring the innate immune response in the tumor microenvironment. Highly selective dual Mer/Axl kinase inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae4c719e098004f12a5992670f8e8abc
https://doi.org/10.1021/acs.jmedchem.1c00920
https://doi.org/10.1021/acs.jmedchem.1c00920
Autor:
Amir Azam, Fernando Avecilla, Nashrah Sharif Khan, Aysha Gaur, Mudasir Nabi Peerzada, Md. Imtaiyaz Hassan, Parvez Khan
Publikováno v:
New Journal of Chemistry. 44:16626-16637
Microtubule affinity-regulating kinase 4 (MARK4) is a serine/threonine kinase involved in the phosphorylation of MAP proteins that regulates microtubule dynamics and abets tumor progression by participating in oncogenic signaling pathways. It is over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3170e690f7d688e5b056d915460c5a67
https://doi.org/10.1039/d0nj03474f
https://doi.org/10.1039/d0nj03474f
Autor:
Minghui Ji, Yi Hou, Yasheng Zhu, Jiaxing Li, Wenbin Kuang, Weijiao Chen, Wenjian Min, Kai Yuan, Peng Yang, Xiao Wang, Liping Wang
Publikováno v:
European journal of medicinal chemistry. 228
Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play determinant roles in MM, but no remarkable progress has been obtained from clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb7ae68acda84a4a6db8591af1d091f
https://pubmed.ncbi.nlm.nih.gov/34875521
https://pubmed.ncbi.nlm.nih.gov/34875521
Autor:
Liming Deng, Bing Liu, Zongtao Zhou, Yueming Chen, Luyong Zhang, Zheng Li, Lijun Hu, Yawen Xu
Publikováno v:
European Journal of Medicinal Chemistry. 164:352-365
The free fatty acid receptor 1 (FFA1 or GPR40) and peroxisome proliferator-activated receptor δ (PPARδ) have attracted a lot of attention due to their role in promoting insulin secretion and sensibility, respectively, which are two major features o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fc2a34935c6b2bb9d217575d6656189
https://doi.org/10.1016/j.ejmech.2018.12.069
https://doi.org/10.1016/j.ejmech.2018.12.069
Publikováno v:
Journal of Medicinal Chemistry. 62:1054-1066
JAK family kinases are important mediators of immune cell signaling and Janus Kinase 3 (JAK3) has long been indicated as a potential target for autoimmune disorders. Intensive efforts to develop highly selective JAK3 inhibitors have been underway for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d9627ef0a111133e1141f60acf50d1
https://doi.org/10.1021/acs.jmedchem.8b01823
https://doi.org/10.1021/acs.jmedchem.8b01823
Autor:
Kang Chang, Qinjie Shi, Weiping Zhu, Jianqin Chen, Xuhong Qian, Shi Yanxia, Yufang Xu, Zhenjiang Zhao, Li Baoju
Publikováno v:
RSC Advances. 9:36204-36207
Due to the emergence of drug resistance, pesticide residue and environmental contamination, it is important to develop novel eco-friendly strategies to protect plants. Among them, plant activators have been gaining more and more attention. Herein, ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::059b27b806d1674c2dfd6e25e65aaf81
https://doi.org/10.1039/c9ra06892a
https://doi.org/10.1039/c9ra06892a
Publikováno v:
Oxidative Medicine and Cellular Longevity, Vol 2021 (2021)
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity
In this study, a chemical investigation on the fruits of Livistona chinensis (FLC) led to the isolation and identification of 45 polyphenols and 5 alkaloids, including two new compounds (Livischinol (1) and Livischinine A (46)), an undescribed compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685a339f54ea3809535411dbf99d50de
https://doaj.org/article/829a19031e204ffabcbede29dda03ee9
https://doaj.org/article/829a19031e204ffabcbede29dda03ee9
Autor:
Thomas W. Gero, John Thomas Feutrill, Bailing Chen, Nathanael S. Gray, Feru Frederic, Brian J. Groendyke, Hilary Szabo, Zhengnian Li, Bin Li, David A. Scott, Chelsea E. Powell
Publikováno v:
Bioorganicmedicinal chemistry letters. 30(19)
The protein kinase TNK2 (ACK1) is an emerging drug target for a variety of indications, in particular for cancer where it plays a key role transmitting cell survival, growth and proliferative signals via modification of multiple downstream effectors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::220bb5eba35eecf2c507de3c0f2c8533
https://pubmed.ncbi.nlm.nih.gov/32739400
https://pubmed.ncbi.nlm.nih.gov/32739400
Autor:
Nicolas Gaboriaud-Kolar, Alexios-Leandros Skaltsounis, Despina Smirlis, Antonia Efstathiou, Cássio Santana Meira, Milena Botelho Pereira Soares, Konstantina Vougogiannopoulou, Vinícius Pinto Costa Rocha, Tanira Matutino Bastos
Publikováno v:
Virulence
Virulence, Vol 9, Iss 1, Pp 1658-1668 (2018)
Virulence, Vol 9, Iss 1, Pp 1658-1668 (2018)
Current treatment for combatting Chagas disease, a life-threatening illness caused by the kinetoplastid protozoan parasite Trypanosoma cruzi is inadequate, and thus the discovery of new antiparasitic compounds is of prime importance. Previous studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3dd19a7698b0ee4b78aa9ba739ed6e1
http://europepmc.org/articles/PMC7000199
http://europepmc.org/articles/PMC7000199